Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
14
Active, not recruiting, industry sponsors, Cardiovascular and metabolic, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed906
14 trials
Showing 1 to 14, recently updated first.
- A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 DiabetesPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05433584 · 794 participants · Start Aug 1, 2022 · Primary completion Oct 21, 2025
Drug: Tirzepatide; Antihyperglycemic medication · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Canoga Park, California; Huntington Park, California · 90 sites in all
- EVOLVE-MI: EVOLocumab Very Early After Myocardial InfarctionPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT05284747 · 6,019 participants · Start Oct 26, 2022 · Primary completion May 29, 2027
Drug: Evolocumab; Routine Lipid Management · For: Cardiovascular Disease; Myocardial Infarction; Stroke and 1 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Huntsville, Alabama · 120 sites in all
- A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard TreatmentPivotal-lookingActive, not recruiting
Dr. Willmar Schwabe GmbH & Co. KGIndustry
NCT07220538 · 400 participants (planned) · Start Nov 28, 2025 · Primary completion Dec 31, 2027
Drug: Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.) · For: Ischemic Stroke Hospitalized; Impairment, Cognitive
Sites: Anyang, China; Baotou, China; Beijing, China · 34 sites in all
- Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic StrokePivotal-lookingActive, not recruiting
Pharmazz, Inc.Industry
NCT05955326 · 160 participants (planned) · Start Jan 8, 2024 · Primary completion Dec 18, 2026
Drug: Sovateltide · For: Acute Cerebral Ischemia
Sites: Guntur, India; Amravati, India; Kota, India · 6 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06864026 · 200 participants (planned) · Start Mar 6, 2025 · Primary completion Aug 2027
Drug: Tirzepatide · For: Psoriatic Arthritis; Overweight or Obesity
Sites: Avondale, Arizona; Chandler, Arizona; Flagstaff, Arizona · 55 sites in all
- A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06112743 · 63 participants · Start Jan 24, 2024 · Primary completion Jul 16, 2026
Drug: Mavacamten · For: Cardiomyopathy, Hypertrophic
Sites: West Hollywood, California; Atlanta, Georgia; Boston, Massachusetts · 23 sites in all
- A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or ObesityActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07438444 · 344 participants (planned) · Start Feb 27, 2026 · Primary completion Jul 2027
Drug: Tirzepatide · For: Diabetes Mellitus, Type 2; Obesity; Overweight
Sites: Ahmedabad, India; Ajmer, India; Allahabād, India · 21 sites in all
- STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight LossActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06571383 · 500 participants (planned) · Start Sep 17, 2024 · Primary completion Nov 15, 2028
Drug: Semaglutide · For: Obesity
Sites: Escondido, California; Orlando, Florida; Tallahassee, Florida · 93 sites in all
- A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)Active, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07004972 · 50 participants (planned) · Start Sep 4, 2025 · Primary completion Dec 13, 2027
Drug: Mavacamten · For: Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sites: Hyderabad, India; Ahmedabad, India; Surat, India · 24 sites in all
- Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)Pivotal-lookingActive, not recruiting
Currax PharmaceuticalsIndustry
NCT06098079 · 8,600 participants (planned) · Start Jan 3, 2024 · Primary completion Jan 2029
Drug: Naltrexone-Bupropion (NB) Combination; Placebo · For: Obesity
Sites: Birmingham, Alabama; Cullman, Alabama; Mobile, Alabama · 140 sites in all
- Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated TriglyceridesActive, not recruiting
JW PharmaceuticalIndustry
NCT07442630 · 88 participants · Start Aug 21, 2023 · Primary completion Jan 22, 2026
Drug: Pitavastatin 4mg; Ezetimibe 10 mg and 2 more · For: Hypercholesterolemia
Sites: Seoul, South Korea
- Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential HypertensionPivotal-lookingActive, not recruiting
Yuhan CorporationIndustry
NCT06041529 · 198 participants · Start Oct 18, 2023 · Primary completion Feb 28, 2026
Drug: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg; Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg · For: Essential Hypertension
Sites: Wŏnju, South Korea; Seoul, South Korea; Busan, South Korea · 15 sites in all
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial HypertensionActive, not recruiting
United TherapeuticsIndustry
NCT05203510 · 52 participants · Start Oct 20, 2022 · Primary completion Apr 30, 2026
Drug: Parenteral Treprostinil; Oral Treprostinil · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Fresno, California; Los Angeles, California · 28 sites in all
- A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)Pivotal-lookingActive, not recruiting
Alimera SciencesIndustry
NCT04469595 · 300 participants (planned) · Start Aug 31, 2020 · Primary completion Dec 31, 2024
Drug: Iluvien 0.19 MG Drug Implant; Aflibercept · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 40 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.